REGENERATIVE ORTHOPEDICS & SPORTS MEDICINE

Britecyte Receives $1M Maryland Grant to Advance Novel Adipose Tissue Therapy for Osteoarthritis

- Britecyte has secured a $1 million clinical grant from the Maryland Stem Cell Research Fund to advance its Adipose Tissue Allograft (BRC-OA) therapy for osteoarthritis treatment. - The FDA has accepted the company's Investigational New Drug application for a First-in-Human Phase 1/2a clinical study targeting knee osteoarthritis. - The multicenter, randomized, single-blind, dose-finding study represents a potential breakthrough for a disease with no approved disease-modifying treatments. - The collaboration between Britecyte, Amarex, and Regenerative Orthopedics & Sports Medicine aims to develop a therapy that could reverse osteoarthritis progression.